Novo welcomes new CEO with guidance cut and $67B loss in value

Novo Nordisk lowered guidance Tuesday, then half an hour later announced Maziar Mike Doustdar will become president and CEO on Aug. 7, the day after the company releases its 2Q25 earnings. He is taking over from Lars Fruergaard Jørgensen, whose departure was announced in May. 

Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO) lowered full-year growth sales growth expectations  to 8-14%, from 13-21% guided in May. EBIT growth was cut to 10-16%, from 16-24%...